Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-27T19:06:49.638Z Has data issue: false hasContentIssue false
  • English
  • Français

Augmentation strategies in the treatment of major depressive disorder

Published online by Cambridge University Press:  23 March 2020

S. Bise ,
B. Kurtovic ,
D. Begic  and
O. Cemalovic
S. Bise*
Affiliation:
Psychiatric Hospital, women, Sarajevo, Bosnia and Herzegovina
B. Kurtovic
Affiliation:
Psychiatric Hospital, women, Sarajevo, Bosnia and Herzegovina
D. Begic
Affiliation:
Psychiatric Hospital, Intensive care, Sarajevo, Bosnia and Herzegovina
O. Cemalovic
Affiliation:
Psychiatric Hospital, Intensive care, Sarajevo, Bosnia and Herzegovina
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Augmentation strategies for the treatment of Major depressive disorder (MDD) are needed when patients with MDD have a partial, or not responded to antidepressant monotherapy. The focus of augmentation therapy has been combining an antidepressant (AD) medication with another AD. Atypical antipsychotics (AAP) are becoming commonly used to augment antidepressants. Beyond AD and AAP, alternative augmentation strategies include mood stabilizers (MS).

Aim

To analyze the characteristics of therapy in patients with diagnosis of MDD and to investigate the frequency of augmentation therapy.

Method

Study included 28 patients hospitalized during one year with MDD diagnosis. Statistical analysis was performed with x2 and t-test.

Result

Among patients with MDD there were 18 (64.28%) women with an average age 57.5 and 10 (35.71%) men with an average age 53.5. Of the 28 patients with MDD, 25 (89.28%) were treated with a combination therapy, and monotherapy in the remaining 3 patients (10.71%). Of 25 patients with augmentation strategy treatment, 22 (88%) used two medications and the remaining 3 (12%) tree psychotropic medications (AAP, AD, MS). The most frequent combinations were a combination of AD and AAP (17 patients, 68%). Beyond that frequent combination were AD and MS (6 patients, 24%). Two patients used combination two AAP, and one patient with two AD and one patients used AAP and MS.

Conclusion

Augmentation strategy is often used in patients with MDD. There is no significant difference in the use combination therapy based on gender and age.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EV484
Information
European Psychiatry , Volume 33 , Issue S1: Abstracts of the 24th European Congress of Psychiatry , March 2016 , pp. S407
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.